Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease

INTRODUCTION HER2-low breast cancer is a gradually recognized and unexplored group of diseases. We aimed to investigate the clinical and prognosis features and to identify the role of stromal tumor-infiltrating lymphocytes (sTILs) in this population. METHODS Consecutive primary breast cancer patients treated between January 2009 to June 2013 were retrospectively reviewed. HER2-low was defined as immunohistochemistry (IHC) 1+, or 2+ and fluorescence in situ hybridization (FISH) negative. sTILs were scored following the international guidelines. Clinicopathologic features and survival were compared according to HER2 and sTILs category. RESULTS A total of 973 breast cancer patients were enrolled, including 615 (63.2%) HER2-low patients. HER2-low patients shared more similarity with HER2-0 cases in clinicopathological features. sTILs in HER2-Low patients was comparable to HER2-0 patients (p = 0.064), both significantly lower than HER2-positive ones (p < 0.001). Meanwhile, tumors with sTILs ≥50% accounted for the least proportion of HER2-low cases (p < 0.001). HER2 status had no significant influence on recurrence-free survival (RFS, p = 0.901) in the whole population. However, in the estrogen receptor (ER)-negative subgroup, HER2-low was related to worse RFS (p = 0.009) and OS (p = 0.001) compared with HER2-positive ones. sTILs increment was an independent favorable prognostic factor in the whole (OS, p = 0.003; RFS, p = 0.005) and HER2-low population (OS, p = 0.007; RFS, p = 0.009) after adjusted to clinicopathological parameters. CONCLUSIONS HER2-low patients shared similar clinicopathological features with HER2-0 rather than HER2-positive cases and had relatively low sTILs. ER-negative/HER2-low patients had significantly inferior survival. sTILs increment was independently associated with favorable survival in the HER2-low group, suggesting a potential benefit from a novel treatment strategy.

[1]  K. Shen,et al.  Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients , 2022, European journal of medical research.

[2]  M. Smid,et al.  HER2-low breast cancer shows a lower immune response compared to HER2-negative cases , 2022, Scientific Reports.

[3]  L. Pusztai,et al.  Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. , 2022, JAMA oncology.

[4]  R. Greil,et al.  Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry , 2021, Breast Cancer Research.

[5]  J. Ramos,et al.  Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers , 2021, Cancers.

[6]  O. Dizdar,et al.  HER2-low breast cancer could be associated with an increased risk of brain metastasis , 2021, International Journal of Clinical Oncology.

[7]  W. Rui,et al.  Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer , 2021, Cancer medicine.

[8]  M. Lux,et al.  Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. , 2021, European journal of cancer.

[9]  Jianxin Chen,et al.  Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer. , 2021, European journal of cancer.

[10]  K. Shen,et al.  Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients , 2021, Frontiers in Oncology.

[11]  C. Sotiriou,et al.  HER2-Low Breast Cancer: Molecular Characteristics and Prognosis , 2021, Cancers.

[12]  Amy M. Sitapati,et al.  NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  N. Pondé,et al.  HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer , 2021, Breast Cancer Research and Treatment.

[14]  H. Iwata,et al.  The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status , 2021, Breast Cancer.

[15]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[16]  A. Lluch,et al.  Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer , 2021, NPJ breast cancer.

[17]  Ming Liu,et al.  Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis , 2020, BMC Cancer.

[18]  A. Vingiani,et al.  Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer , 2020, Breast Cancer Research and Treatment.

[19]  A. Sapino,et al.  Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. , 2020, Seminars in cancer biology.

[20]  H. Horlings,et al.  Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. , 2020, European journal of cancer.

[21]  D. Sirohi,et al.  American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory. , 2019, American journal of clinical pathology.

[22]  K. Shen,et al.  Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study , 2019, Cancer research and treatment : official journal of Korean Cancer Association.

[23]  R. Greil,et al.  HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer , 2019, International journal of molecular sciences.

[24]  A. Brandes,et al.  Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  T. Nielsen,et al.  Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.

[26]  M. Disis,et al.  Clinical significance of tumor-infiltrating lymphocytes in breast cancer , 2016, Journal of Immunotherapy for Cancer.

[27]  T. Fehm,et al.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer , 2016, Journal of Cancer Research and Clinical Oncology.

[28]  F. Cardoso,et al.  The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review , 2015, Breast Cancer Research.

[29]  Carsten Denkert,et al.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.

[30]  R. Jordan,et al.  Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages , 2015, The Journal of Immunology.

[31]  T. Ignatov,et al.  Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade , 2015, Breast Cancer Research and Treatment.

[32]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[34]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[35]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[36]  Lin Lin,et al.  Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease? , 2018, European journal of cancer.

[37]  E. Perez,et al.  Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. , 2016, JAMA oncology.